Clinical Trial News Archive
Get news by email or subscribe to our news feeds.
News Archive for December 2012
December 3, 2012
- Alkermes and Collaborators to Present Data from Three Ongoing Clinical Development Programs at Two Major Medical Meetings
- Innavirvax: the Phase I/Iia Clinical Study of Its VAC-3S Immunotherapeutic Vaccine in the Treatment of HIV Infection Has Achieved Its Primary Endpoint
- Largest Ever Study of Clostridium Difficile Infection to Attempt to Reveal True Incidence of Disease
- Upsher-Smith Presents Favorable Phase I Data for USL261, a Novel Formulation of Intranasal Midazolam, in Patients With Epilepsy
- Promising drug slows down advance of Parkinson's disease and improves symptoms
- The Staby Technology from Delphi Genetics Efficiently Applied To DNA-Vaccine
- Results of Long-Term, Open-Label Extension Study Evaluating ONFI (clobazam) CIV Presented at American Epilepsy Society Annual Meeting
- Three-Year Data From Sabril (vigabatrin) Registry Presented at American Epilepsy Society Annual Meeting
- ImmunoGen, Inc. Announces Clinical Data Presentations at the 54th ASH Annual Meeting and Exposition
- Forest Laboratories, Inc. to Present Cariprazine Results from a Phase 3 Trial and Two Pharmacology Studies at the American College of Neuropsychopharmacology (ACNP) Annual Meeting
- ARIAD Announces Ponatinib Presentations at Annual American Society of Hematology Meeting
December 4, 2012
- Compugen Presents at American Association of Cancer Research Special Conference on Tumor Immunology
- UCB Announces New Data to Increase Understanding of Short- and Long-Term Clinical Profile of Antiepileptic Drug VIMPAT (lacosamide)
- New Pharmacoeconomic Analysis Shows Lower Rate of Reintubation Observed With SURFAXIN Treatment May Reduce Hospital Costs Associated with Bronchopulmonary Dysplasia
- Study Examines Psychotropic Medication Use Among U.S. Adolescents with Mental Disorders
December 5, 2012
- The 12nd Colloque Médecine et Recherche of the Fondation IPSEN in the Endocrinology series: ?Hormones, intrauterine health and programming?
- Chelsea Therapeutics Announces Northera (Droxidopa) Study 306B Meets Primary Endpoint
- Photocure Announces Positive Results of Cevira Study Results Demonstrate Significant Efficacy in Treatment of Lesions and Oncogenic Human Papilloma Virus in Patients With Precancerous Lesions of the Cervix
December 6, 2012
- Cancer Vaccine Specialist Scancell's SCIB1 Phase 1/2 Clinical Trial Reports Preliminary Evidence of Immune Response and Clinical Benefit
- New Long-Term Study Suggests Lower Mortality in Alzheimer's Patients Treated with Galantamine Versus Placebo Significantly Lesser Cognitive Decline Also Seen in Treatment Group Compared to Placebo Group
- Phase II Data Presented at ACNP 2012 Shows Novel Antidepressant GLYX-13 Significantly Reduces Depression Scores Within Hours
- Fostering Access to Innovative Medicines in Indonesia
- NICE Draft Guidance Recommends Wider Use of Abatacept in Treating Rheumatoid Arthritis
- Judgment in Case C-457/10 P AstraZeneca v Commission
December 7, 2012
- Dr. Reddy's Launches Debiopharm's Pamorelin LA in India for the Treatment of Locally Advanced or Metastatic, Hormone-Dependent Prostate Cancer
- PROLOR Biotech To Present Preclinical Data On Its Long-Acting Clotting Factor Vlla At 2012 ASH Annual Meeting
- Spectrum Pharmaceuticals Highlights 19 Abstracts at the 54th Annual Meeting of the American Society of Hematology (ASH), Atlanta, Georgia, December 8-11, 2012
- Phase III Study Results Of Halaven (eribulin mesylate) Injection In Metastatic Breast Cancer Presented At SABCS
- Positron Announces Strontium Sale
- The Multiple Myeloma Research Foundation (MMRF) and Multiple Myeloma Research Consortium (MMRC) to Present 11 Oral or Poster Sessions at the 54th Annual American Society of Hematology (ASH) Meeting
- NICE Consults on Preliminary Recommendations for a New Kidney Cancer Drug
- Qualitest Issues Voluntary, Nationwide Recall of 101 Lots of Hydrocodone Bitartrate and Acetaminophen Tablets, USP 10 mg/500 mg Due to the Potential for Oversized Tablets
- Medbox, Inc. Commences Pursuit of Strategic Acquisitions
- Results from a Phase 3 Study Show Iroko's Investigational Submicron Indomethacin Provided Effective Pain Relief at Lower Doses
- Stemline Therapeutics, Inc. Announces Presentations of SL-401 Updated Clinical Trial Results in Acute Myeloid Leukemia (AML) and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) and SL-101 Preclinical Efficacy Data Against Hodgkin's Lymphoma at the 54th Annual Meeting of the American Society of Hematology (ASH)
- Bayer Consumer Care Voluntarily Recalls 56 Lots of BRONKAID Caplets Dual Action Formula due to Product Labeling Error
- Prolong TM, a New Revolutionary First Line Treatment for Premature Ejaculation is Licensed in Europe
- Isis Pharmaceuticals Reports Positive Phase 1 Data On Three Drugs In Development To Treat Metabolic Disorders
December 10, 2012
- Nuron Biotech Acquires Commercial, Preventive Vaccine Meningitec from Pfizer
- Sirona Biochem's SGLT Inhibitor Performs Better Than Johnson and Johnson?s SGLT Inhibitor, According to Study
- Concert Pharmaceuticals Presents Findings Demonstrating Enhanced Potency of CTP-221, a Deuterated S-Enantiomer of Lenalidomide
- Long term assessment of TK clinical benefit presented at ASH
- Genentech?s Perjeta Significantly Extends Survival in People With Her2-Positive Metastatic Breast Cancer
- YM BioSciences Reports Phase I/II Data for JAK Inhibitor CYT387 in Myelofibrosis at ASH 2012
- ELIQUIS (apixaban) Demonstrated Superiority In Reducing A Composite Of Recurrent Venous Thromboembolism And All-Cause Death Without Increasing The Rate Of Major Bleeding Versus Placebo During One Year Of Extended Treatment
- Isotechnika Pharma's Nicam Compounds Demonstrate Positive Anti-Hepatitis C Virus Activity in Secondary Level Testing at Nih-Funded Labs
- Inovio's Synthetic Flu Vaccine Doubles Rate of Elderly Subjects Displaying Protective Immune Responses
- Phase II Data Presented at Acnp 2012 Shows Novel Antidepressant Glyx-13 Significantly Reduces Depression Scores Within Hours
- Presentations Highlight Data on Velcade (bortezomib) as Retreatment or Maintenance in Patients with Multiple Myeloma
- Once a Week Oral Proteasome Inhibitor MLN9708-Based Therapy Showed High Response Rates in Front-Line Multiple Myeloma Phase 1 / 2 study
- TetraLogic Pharmaceuticals Announces Presentation on Smac Mimetic Birinapant at American Society of Hematology (ASH) Annual Meeting
- AMAG Pharmaceuticals Announces New Data from Ferumoxytol Pivotal Phase III Broad Iron Deficiency Anemia Program Presented at ASH
- New Data Highlighting Long-Term Efficacy and Safety Outcomes of PNH Patients Treated with Soliris® Reported at ASH Annual Meeting
- Study Identifies Targeted Molecular Therapy for Untreatable NF1 Tumors
- Imprime PGG in Combination with Monoclonal Antibody Therapy Achieves 64% Complete Response Rate in Chronic Lymphocytic Leukemia Patients
- Boehringer Ingelheim Presents New Phase II Data for Volasertib in Adult Patients with AML
- Baxter Presents Phase I/III Data Evaluating Safety and Efficacy of BAX 326, an Investigational Recombinant Factor IX for Hemophilia B, Showing More Than 40 Percent of Patients Experienced No Bleeds
- New Studies Reveal Critical Insights To Improve Care Of Patients With Sickle Cell Disease
- Neuralstem Investigator Presents New ALS NSI-566 Data at International Symposium on ALS/MND
- Medication Errors from Injectable Drugs Harm One Million Inpatients Each Year Adding Billions in Cost, New Study Finds
- ARIAD Announces 12-Month Data from Pivotal PACE Trial of Ponatinib in Heavily Pretreated Chronic-Phase CML Patients
- Seattle Genetics Reports Data from Phase I Trial of ADCETRIS (Brentuximab Vedotin) in Front-line Mature T-Cell Lymphomas (MTCL)
- Phase II Trial of Sanofi JAK2 Inhibitor in Myelofibrosis Met Primary Endpoint
- Array BioPharma Provides Updates On Clinical Data At The 2012 American Society Of Hematology Meeting
- Novartis long-term Phase III data show Ph+ CML patients on Tasigna achieved significantly deeper molecular response versus Gleevec
- Anacor Pharmaceuticals Announces Positive Results From Phase 2 Trial of AN2728 in Adolescents With Atopic Dermatitis
- American Heart Association joins the Alliance for Rational Use of NSAIDs
- Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
- Data Reported From Phase 1 Study of Once a Week MLN9708 Oral Proteasome Inhibitor in Patients with Relapsed or Refractory Systemic Light-Chain Amyloidosis
- ImmunoGen, Inc. Announces IMGN901 Clinical Data Presented at ASH
- Tanzania Expands Immunization Program To Include Pfizer's Prevenar 13 For Prevention Of Pneumococcal Disease
- Seattle Genetics Reports Data from Phase I Trial of ADCETRIS (Brentuximab Vedotin) in Front-line Hodgkin Lymphoma at ASH Annual Meeting
- Preclinical Results for Acetylon Pharmaceuticals' Selective HDAC1/2 Inhibitor for the Treatment of Sickle Cell Disease and Beta-Thalassemia Presented at ASH 2012
- Onconova Presents Positive Clinical Results for Rigosertib at ASH Meeting
- Clinical and Preclinical Results for Acetylon Pharmaceuticals' ACY-1215 for the Treatment of Multiple Myeloma Presented at the 54th Annual Meeting of the American Society of Hematology
- New Data for Jakafi (ruxolitinib) Presented at the 2012 American Society of Hematology Annual Meeting
- Seattle Genetics Announces Data from Investigator-Sponsored Trials of ADCETRIS (Brentuximab Vedotin) in Cutaneous T-Cell Lymphoma at ASH Annual Meeting
- ARIAD Announces Long-Term Molecular Response Data on Ponatinib
December 11, 2012
- Sucampo Receives $15 Million Milestone Payment from Abbott on First Sale of Amitiza (lubiprostone) in Japan
- Merrimack Pharmaceuticals Presents Promising Phase I Clinical Data for Novel Agent to Treat HER2-positive Breast Cancer and Preclinical Data on Companion Diagnostic
- Senesco Provides Summary of SNS01-T Progress in Phase 1b/2a Trial
- Seattle Genetics Highlights Data Presentations from Genentech ADC Collaborator Programs at ASH Annual Meeting
- Adaptimmune Announces Preliminary Results from an Early Phase Trial of Gene Engineered T Cells Targeting Cancer Testis Antigens in Multiple Myeloma
- Aceto Subsidiary, Rising Pharmaceuticals, Launches First Generic Version of Grifulvin V
- Two-Year Data Show New Novartis Drug Jakavi Significantly Reduced Myelofibrosis Disease Burden and Suggest Overall Survival Advantage
- OXiGENE Announces Presentation of Encouraging OXi4503 Preclinical and Clinical Data in Acute Myelogenous Leukemia at American Society of Hematology Meeting
- Addition of Epratuzumab to Combination Chemotherapy May be Beneficial in Acute Lymphocytic Leukemia
- Lotus Pharmaceutical Company Inc. Filed Its Abbreviated New Drug Application (ANDA) Containing a Paragraph IV Certification for a Generic Version of Xenical(R) with the U.S. Food & Drug Administration (FDA)
- Aeterna Zentaris: Final Phase 2 Data Demonstrate Perifosine and Sorafenib Combination Therapy Well Tolerated by Heavily Pretreated Lymphoma Patients
- Almirall and Forest Laboratories announce commercial availability of Tudorza Pressair in U.S. pharmacies
- Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, Suggest High and Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma
- Durata Therapeutics Announces Phase 3 Clinical Trial Results for Dalbavancin in the Treatment of ABSSSI
- Alnylam Presents New Pre-clinical Data on RNAi Therapeutics for the Treatment of Hemophilia and Other Bleeding Disorders at 54th American Society of Hematology (ASH) Annual Meeting
- Seattle Genetics Highlights Adcetris (Brentuximab Vedotin) Data in Relapsed Hodgkin Lymphoma and Other CD30-Positive Malignancies from Multiple Presentations at ASH Annual Meeting
- Infinity Reports IPI-145 Phase 1 Data Showing Clinical Activity in B-Cell and T-Cell Malignancies at ASH Annual Meeting
- Astex Pharmaceuticals Announces Results From Dose Escalation Part of SGI-110 Phase 1/2 MDS and AML Study in an Oral Presentation at ASH
- Metformin improves blood glucose levels and BMI in very obese children
- Brain angioplasty and stents found safe and effective for stroke patients
- Novel Drug Therapy Targets Aggressive Form of Non-Hodgkin's Lymphoma
- Syneron Launches New Sublative iD Focal Tip To Reduce Fine Wrinkles in Hard to Reach Areas Around the Eyes and Mouth
- Eisai Granted Additional Six Month U.S. Marketing Exclusivity For Aciphex (Rabeprazole Sodium)
- BrainStorm's Outstanding ALS Clinical Data Chosen to Kick-Off the Israel Neurological Association Meeting
- Endo Health Solutions Launches 7.5mg and 15mg strengths of Reformulated, Designed to be Crush-Resistant, OPANA ER
- Celldex Therapeutics' CDX-301 Safely Mobilizes Hematopoietic Cells in Phase 1 Study; Future Development Planned
- Celator Pharmaceuticals Announces Data on the Effects of CPX-351 in High Risk AML Presented at the ASH Annual Meeting
- Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, in Relapsed/Refractory Mantle Cell Lymphoma Presented at American Society of Hematology Annual Meeting
- Vaccine offers promise as post-surgery treatment for pancreatic cancer patients
- Pharmacyclics Announces Updated Results for BTK Inhibitor Ibrutinib (PCI-32765) at American Society of Hematology (ASH) Annual Meeting
December 12, 2012
- Aduro Announces Two Presentations at Keystone Meeting
- Positive Results Achieved in Vernalis' Receptor Occupancy Study of V81444 for Parkinson's Disease and Other CNS Indications
- NIH-Funded Trial Launched to Assess Experimental TB Drug
- Unigene's Phase 2 Study of Oral PTH for the Treatment of Osteoporosis in Postmenopausal Women Featured in Bone
- Study Identifies Targeted Molecular Therapy for Untreatable NF1 Tumors
- Gencaro Cardiovascular Effect on Patients with Atrial Fibrillation Paper Published in European Journal of Heart Failure
- Study Finds Loss of Normal Nighttime Parasympathetic Activity in Veterans Suffering from Gulf War Syndrome
- Gencaro Cardiovascular Effect on Patients with Atrial Fibrillation Paper Published in European Journal of Heart Failure
- XBiotech Announces Positive Phase II Clinical Trial Results for Lead Candidate MABp1 in Acne Vulgaris
December 13, 2012
- AstraZeneca Announces Top-Line Results of OSKIRA-4 Phase IIb Study of Fostamatinib as a Monotherapy for Rheumatoid Arthritis
- Clinical Data from NewLink Genetics' HyperAcute Prostate Cancer Immunotherapy Published in Journal of Immunotherapy
- Auxilium Pharmaceuticals Announces Encouraging Top-line 30-Day Data from XIAFLEX (CCH) Phase Ib Study in Cellulite
- Oncolytics Biotech Inc. Announces Positive Top Line REOLYSIN Data for First Endpoint in Randomized Phase III Study in Head and Neck Cancers
- Insero Health Completes Phase I Trial of Novel Therapy in Patients With Drug Resistant Epilepsy
- Spectrum Pharmaceuticals Highlights Promising ZEVALIN, FOLOTYN and Belinostat Clinical Data Presented at the 54th Annual Meeting of the American Society of Hematology
- Inspiration Biopharmaceuticals Highlights Positive Interim Data on its Two Lead Investigational Product Candidates: Recombinant Porcine FVIII (OBI-1) and Recombinant Factor IX (IB1001)
December 14, 2012
- AcelRx to Present Top-Line Data from Phase 3 Study of Sufentanil NanoTab PCA System vs. IV PCA Morphine at the 66th Annual PostGraduate Assembly in Anesthesiology held in New York City
- BioSpecifics Technologies Corp. Announces Top-Line 30-Day Data from XIAFLEX Phase Ib Study for Treatment of Cellulite
- Genzyme and Isis Provide Update on CHMP Opinion on KYNAMRO (mipomersen)
- Bayer Submits New Drug Application for Radium Ra 223 Dichloride for the Treatment of Castration-Resistant Prostate Cancer (CRPC) with Bone Metastases
December 17, 2012
- Antares Pharma Announces Submission of New Drug Application for OTREXUP
- Roche?s Breast Cancer Treatment Perjeta Receives Recommendation for Approval in EU
- Single Administration of GenVec's Vaccine Provides Protective Immunity Against HSV in Pre-clinical Animal Models
- Major Breakthrough in HIV Research: Study Published Today Online in The Journal of Experimental Medicine Identifies Population of Cells Serving as the Major Reservoir for HIV
- Lexicon's Drug Candidate For Irritable Bowel Syndrome Receives Fast Track Status From The FDA
- Preclinical Study Provides Potential Mechanisms for Lower Cardiotoxicity in Patients with Multiply Relapsed or Refractory Aggressive B-cell NHL Treated with PixuvriTM Who Received Prior Doxorubicin Therapy
December 18, 2012
December 19, 2012
- Merck: Phase III Trial of L-BLP25 (Stimuvax) in Patients with Non-Small Cell Lung Cancer Did not Meet Primary Endpoint
- Actelion's Ponesimod Successful in Mid-stage Trial in Patients with Moderate to Severe Chronic Plaque Psoriasis - Ponesimod to Proceed to Phase III Clinical Development in Psoriasis
- Oncothyreon Announces that L-BLP25 (Stimuvax) Did Not Meet Primary Endpoint of Improvement in Overall Survival in Pivotal Phase 3 Trial in Patients with Non-Small Cell Lung Cancer
- Idera Pharmaceuticals Announces Positive Top-line Results from Phase 2 Trial of IMO-3100 in Patients with Moderate-to-Severe Plaque Psoriasis
- EMD Serono: Phase III Trial of L-BLP25 (Stimuvax) in Patients with Non-Small Cell Lung Cancer Did not Meet Primary Endpoint
- Positive Response from European Regulatory Procedure Supports Approval of Elvanse(lisdexamfetamine dimesylate) for ADHD
- Announcement Regarding Applications for Approval of Pediatric Indication and Additional Formulation of Topina, an Antiepileptic Agent
- GSK and Theravance Announce Regulatory Submission for UMEC/VI (LAMA/LABA) in the US
- Intercell receives CHMP positive opinion for the pediatric indication of its Japanese Encephalitis vaccine in Europe
- Scenesse Successful in Phase Iia Vitiligo Study
- Positive response from European regulatory procedure supports approval of Elvanse® (lisdexamfetamine dimesylate) for ADHD
- Gentium Submit 2nd LoOIs Response to the EMA's CHMP for Defibrotide MAA
- Phase II Study Indicates that Fibrinogen Concentrate Given as a First-Line Therapy Safely Reduces Need for Transfusion after Aortic Surgery
- Actelion's ponesimod successful in mid-stage trial in patients with moderate to severe chronic plaque psoriasis - Ponesimod to proceed to Phase III clinical development in psoriasis
- European Medicines Agency recommends approval of medicine for reduction of alcohol consumption
December 20, 2012
- NEJM Published Study shows Novartis Compound ACZ885 Significantly Relieves Symptoms in Patients with Serious Form of Childhood Arthritis
- Medivir Announces Phase III Data for Simeprevir Demonstrating Efficacy and Safety in Genotype 1 Hepatitis C Patients
- Scientists at The New York Stem Cell Foundation and Columbia University Medical Center Develop Scientific Technique To Help Prevent Inherited Disorders in Humans
- The Medicines Company Announces Positive Trial Results for Oritavancin in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
- Merck Announces HPS2-THRIVE Study of Tredaptive (Extended-Release Niacin/Laropiprant) Did Not Achieve Primary Endpoint
- Gliknik Announces Interim Clinical Data From Use Of Its Immunomodulator Drug Candidate In Multiple Myeloma Patients
- Allergan's Botox (botulinum toxin type A) Receives a Positive Opinion in Fourteen European Countries for Idiopathic Overactive Bladder
- Vivus Announces Express Scripts Adds Qsymia (Phentermine And Topiramate Extended-Release) Capsules CIV To Its Standard Benefits Program
- Truven Health Analytics Poll Finds Americans Split on Medicare Reform
- The National Black Caucus of State Legislators Announces Policy Forecast for 2013 State Legislative Action, Releases December 2012 issue of The Legislator
December 21, 2012
- Spectrum Pharmaceuticals Announces Achievement of Primary Endpoint in Belinostat Registrational Trial
- European Medicines Agency starts review of Tredaptive, Pelzont and Trevaclyn
- Transcept Pharmaceuticals Announces that a Phase 2 Clinical Trial of TO-2061 as Adjunctive Therapy for Obsessive Compulsive Disorder Did Not Meet Primary Endpoint
- Pergamum reports positive Phase II data from clinical trial in outer ear infections
- Angiotech Receives FDA Approval for its Proprietary Bio-Seal Lung Biopsy Device
- Cubist Submits ENTEREG Supplemental NDA
- The CHMP Delivers a Positive Opinion Recommending Grant of Marketing Authorization for ADASUVE(R) (Staccato(R) Loxapine) in the European Union
- Navidea Biopharmaceuticals Submits Lymphoseek Marketing Authorization Application to European Medicines Agency
- Orexigen Therapeutics Concludes Light Study Patient Screening, Expecting to Randomize Approximately 9,000 Patients, and Presents New Obesity Therapeutics Market Research
- Positive Response from European Regulatory Procedure Supports Approval of Elvanse (lisdexamfetamine dimesylate) for ADHD
- e-Therapeutics provides update on progress of ETS2101 cancer trials
- Premier Biomedical Announces Therapeutic Advance in the Treatment and Prevention of Suicide and Depression
- Vanda Announces Positive Phase III Results For Tasimelteon In The Treatment Of Non-24-Hour Disorder
- Breakthrough Study Shows Benefits of Adjunctive L-methylfolate in the Treatment of SSRI-Resistant Major Depressive Disorder
- Allon announces PSP clinical trial results
- New Study Shows that Majority of Acute Migraine Patients Have Cardiovascular Disease Risk Factors and One Third Have Cardiovascular Disease
- R-Tech Ueno: Announcement of Approval of sNDA for RESCULA Ophthalmic Solution and Start of Commercialization
- Saint Luke's research listed among American Heart Association's top 10 research advances for 2012
- Lilly Reaches Agreement with U.S. Securities and Exchange Commission
- Atlantic Pharmaceuticals, Inc. Announces Two Patent Issuances for Its Tamper-Resistant Pharmaceutical Platform
- Pisgah Laboratories Receives Patent for Innovative Abuse-Deterrent Technology Targeting Pseudoephedrine and Ephedrine, Common Ingredients for Methamphetamine Production
- 1977-2012: Science, Technology and Health Care
- Otsuka and Lundbeck Initiate the Regulatory Process for Aripiprazole (Once-Monthly) Depot Formulation in Europe
- Voluntary Product Recall Initiated by Qualitest Pharmaceuticals Impacts Three Lots of Hydrocodone Bitartrate and Acetaminophen Tablets, USP 10 mg/500 mg Repackaged and Distributed by Mylan Institutional
December 27, 2012
- Soligenix Regains North American and European Commercial Rights to Oral BDP
- Promius Pharma, Llc. Announces Sales Force Expansion
December 28, 2012
- A Look At Childhood Cancer And African Americans
- Omeros Reports OMS103HP Phase 3 Clinical Trial Results
- NPS Pharmaceuticals Signs Agreements with Leading Specialty Home Infusion Providers to Support Distribution and Home-based Clinical Care Services for Gattex®
- "Lap Dances," Mortgage Payments and Other Kickbacks Leads to $12.2 Million Settlement With Victory Pharma, Inc. in False Claims Act Case Brought by Ellis & Rapacki LLP
- NovaDel Announces Preliminary Agreement to Sell its NovaMist Technology
- Watson Confirms Velcade Patent Challenge
- MultiCell Technologies Delivered Presentation at 2012 ASCB Meeting
- Endo Pharmaceuticals Returns Urocidin Global Rights to Bioniche Life Sciences Inc.
- Mylan Launches Generic Nordette 28 Tablets
- Depomed Announces Dismissal Of Suit Against Two Gralise ANDA Filers Following Withdrawal Of ANDA And Patent Challenge
- Mylan Launches Generic Dilantin Chewable Tablets
- Emergent BioSolutions Secures Exclusive U.S. Commercial Rights to Next Generation Pandemic Influenza Vaccine Candidate
